Bristol-Myers Squibb Company's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $13,069 million (+6.9% vs a year earlier) |
| Diluted EPS (GAAP) | $1.05 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $1.35 |
| Full-year guidance | Mixed |
Guidance
Revenue guidance raised to ~$49.75–$50.25B; non-GAAP EPS range lowered to $6.35–$6.55 from $6.75–$7.00, including a $(0.60) IPRD/licensing impact.
Why this label: Revenue guide increased to $49.75-$50.25B, but non-GAAP EPS moved down to $6.35-$6.55 from $6.75-$7.00 (IPRD charges): core items in opposite directions.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| revenue (non-GAAP) | FY2026 | ~$49.75–$50.25 billion | ~$49.0–$50.0 billion |
| non-GAAP diluted EPS | FY2026 | $6.35–$6.55 | $6.75–$7.00 |
| other income/(expense) | FY2026 | ~$(650) million | ~$(700) million |
| gross margin | FY2026 | ~69%–70% | ~69%–70% |
| Eliquis worldwide revenue growth | FY2026 | 20%–25% | 20%–25% |
From the release
Revenue: "Total Revenues · $13,069 · $12,222 · 7 · % · 7 · %"
Earnings per share: "GAAP EPS was $1.05 and non-GAAP EPS was $1.35; Both figures include net impact of $(0.58) due to Acquired IPRD charges and licensing income"
revenue (non-GAAP): "Bristol Myers Squibb is increasing its full-year, non-GAAP revenue guidance from a range of approximately $49.0 billion to $50.0 billion to a range of approximately $49.75 billion to $50.25 billion."
non-GAAP diluted EPS: "Diluted EPS · $6.75 - $7.00 · $6.35 - $6.55"
other income/(expense): "Full-year other income/(expense) is now expected to be ~$650 million of expense, due to favorable net interest."
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 revenue guidance to ~$49.75–$50.25 billion; Q3 revenue up 7%.
Source
Bristol-Myers Squibb Company earnings release (SEC filing), accession 0000014272-26-000022, filed 2026-10-29.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.